Selected research
Industry Research
Filgrastim Injection Industry Research Report 2026
Market perspective
The global Filgrastim Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Filgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Filgrastim Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Filgrastim Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Filgrastim Injection include Teva Pharmaceuticals, Novartis AG, Pfizer, Amgen Inc and Accord Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Filgrastim Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Filgrastim Injection Market by Company
Teva Pharmaceuticals
Novartis AG
Pfizer
Amgen Inc
Accord Healthcare
Filgrastim Injection Segment by Type
300mcg/0.5mL (Prefilled Syringe)
300mcg/mL (vial)
480mcg/0.8mL (Prefilled Syringe)
480mcg/1.6 mL (vial)
Filgrastim Injection Segment by Application
Adult Use
Pediatric Use
Geriatric Use
Filgrastim Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Filgrastim Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Filgrastim Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Filgrastim Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Filgrastim Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 300mcg/0.5mL (Prefilled Syringe)
- 300mcg/mL (vial)
- 480mcg/0.8mL (Prefilled Syringe)
- 480mcg/1.6 mL (vial)
Applications
- Adult Use
- Pediatric Use
- Geriatric Use
Companies covered
- Teva Pharmaceuticals
- Novartis AG
- Pfizer
- Amgen Inc
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Filgrastim Injection Market Size (2021-2032)
- 2.2.2 Global Filgrastim Injection Sales (2021-2032)
- 2.2.3 Global Filgrastim Injection Market Average Price (2021-2032)
- 2.3 Filgrastim Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 300mcg/0.5mL (Prefilled Syringe)
- 2.3.3 300mcg/mL (vial)
- 2.3.4 480mcg/0.8mL (Prefilled Syringe)
- 2.3.5 480mcg/1.6 mL (vial)
- 2.4 Filgrastim Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adult Use
- 2.4.3 Pediatric Use
- 2.4.4 Geriatric Use
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Filgrastim Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Filgrastim Injection Sales (K L) of Manufacturers (2021-2026)
- 3.3 Global Filgrastim Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Filgrastim Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Filgrastim Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Filgrastim Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Filgrastim Injection, Product Type & Application
- 3.8 Global Manufacturers of Filgrastim Injection, Established Date
- 3.9 Global Filgrastim Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceuticals
- 4.1.1 Teva Pharmaceuticals Company Information
- 4.1.2 Teva Pharmaceuticals Business Overview
- 4.1.3 Teva Pharmaceuticals Filgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceuticals Filgrastim Injection Product Portfolio
- 4.1.5 Teva Pharmaceuticals Recent Developments
- 4.2 Novartis AG
- 4.2.1 Novartis AG Company Information
- 4.2.2 Novartis AG Business Overview
- 4.2.3 Novartis AG Filgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis AG Filgrastim Injection Product Portfolio
- 4.2.5 Novartis AG Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Filgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Filgrastim Injection Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Amgen Inc
- 4.4.1 Amgen Inc Company Information
- 4.4.2 Amgen Inc Business Overview
- 4.4.3 Amgen Inc Filgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Inc Filgrastim Injection Product Portfolio
- 4.4.5 Amgen Inc Recent Developments
- 4.5 Accord Healthcare
- 4.5.1 Accord Healthcare Company Information
- 4.5.2 Accord Healthcare Business Overview
- 4.5.3 Accord Healthcare Filgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Accord Healthcare Filgrastim Injection Product Portfolio
- 4.5.5 Accord Healthcare Recent Developments
5 Global Filgrastim Injection Market Scenario by Region
- 5.1 Global Filgrastim Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Filgrastim Injection Sales by Region: 2021-2032
- 5.2.1 Global Filgrastim Injection Sales by Region: 2021-2026
- 5.2.2 Global Filgrastim Injection Sales by Region: 2027-2032
- 5.3 Global Filgrastim Injection Revenue by Region: 2021-2032
- 5.3.1 Global Filgrastim Injection Revenue by Region: 2021-2026
- 5.3.2 Global Filgrastim Injection Revenue by Region: 2027-2032
- 5.4 North America Filgrastim Injection Market Facts & Figures by Country
- 5.4.1 North America Filgrastim Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Filgrastim Injection Sales by Country (2021-2032)
- 5.4.3 North America Filgrastim Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Filgrastim Injection Market Facts & Figures by Country
- 5.5.1 Europe Filgrastim Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Filgrastim Injection Sales by Country (2021-2032)
- 5.5.3 Europe Filgrastim Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Filgrastim Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Filgrastim Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Filgrastim Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Filgrastim Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Filgrastim Injection Market Facts & Figures by Country
- 5.7.1 South America Filgrastim Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Filgrastim Injection Sales by Country (2021-2032)
- 5.7.3 South America Filgrastim Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Filgrastim Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Filgrastim Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Filgrastim Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Filgrastim Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Filgrastim Injection Sales by Type (2021-2032)
- 6.1.1 Global Filgrastim Injection Sales by Type (2021-2032) & (K L)
- 6.1.2 Global Filgrastim Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Filgrastim Injection Revenue by Type (2021-2032)
- 6.2.1 Global Filgrastim Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Filgrastim Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Filgrastim Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Filgrastim Injection Sales by Application (2021-2032)
- 7.1.1 Global Filgrastim Injection Sales by Application (2021-2032) & (K L)
- 7.1.2 Global Filgrastim Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Filgrastim Injection Revenue by Application (2021-2032)
- 7.2.1 Global Filgrastim Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Filgrastim Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Filgrastim Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Filgrastim Injection Value Chain Analysis
- 8.1.1 Filgrastim Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Filgrastim Injection Production Mode & Process
- 8.2 Filgrastim Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Filgrastim Injection Distributors
- 8.2.3 Filgrastim Injection Customers
9 Global Filgrastim Injection Analyzing Market Dynamics
- 9.1 Filgrastim Injection Industry Trends
- 9.2 Filgrastim Injection Industry Drivers
- 9.3 Filgrastim Injection Industry Opportunities and Challenges
- 9.4 Filgrastim Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst